

ASX ANNOUNCEMENT

COMPANY SECRETARY APPOINTMENT AND RESIGNATION

SYDNEY, Thursday, 27 April 2017: Cellmid Limited (ASX: CDY) wishes to advise that the Board of Directors appointed Mr Raymond Ting as Company Secretary, effective 1 May 2017. With a background in audit and financial management Raymond has been working at Cellmid as Financial Controller since April 2017 and has previously held accounting roles in ASX listed companies.


The Board also wishes to advise the resignation of Ms Aliceson Rourke as Company Secretary, effective 1 May 2017. The directors thank Aliceson for her contribution to the Company during her tenure and wish her well in her future endeavours.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalsz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to this novel target is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia and Japan, and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.